Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.

Watkins JD, Lancelot S, Campbell GR, Esquieu D, de Mareuil J, Opi S, Annappa S, Salles JP, Loret EP.

Retrovirology. 2006 Jan 27;3:8.

2.

HIV-1 Tat protein enhances microtubule polymerization.

de Mareuil J, Carre M, Barbier P, Campbell GR, Lancelot S, Opi S, Esquieu D, Watkins JD, Prevot C, Braguer D, Peyrot V, Loret EP.

Retrovirology. 2005 Feb 3;2:5.

3.

The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis.

Campbell GR, Pasquier E, Watkins J, Bourgarel-Rey V, Peyrot V, Esquieu D, Barbier P, de Mareuil J, Braguer D, Kaleebu P, Yirrell DL, Loret EP.

J Biol Chem. 2004 Nov 12;279(46):48197-204. Epub 2004 Aug 24.

4.

Full-length HIV-1 Tat protein necessary for a vaccine.

Opi S, Péloponèse JM Jr, Esquieu D, Watkins J, Campbell G, De Mareuil J, Jeang KT, Yirrell DL, Kaleebu P, Loret EP.

Vaccine. 2004 Aug 13;22(23-24):3105-11.

PMID:
15297062
5.

A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.

Montembault M, Vo-Thanh G, Deyine A, Fargeas V, Villiéras M, Adjou A, Dubreuil D, Esquieu D, Grégoire C, Opi S, Péloponèse JM, Campbell G, Watkins J, de Mareuil J, Aubertin AM, Bailly C, Loret E, Lebreton J.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1543-6.

PMID:
15006399
6.

Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.

Opi S, Péloponèse JM Jr, Esquieu D, Campbell G, de Mareuil J, Walburger A, Solomiac M, Grégoire C, Bouveret E, Yirrell DL, Loret EP.

J Biol Chem. 2002 Sep 27;277(39):35915-9. Epub 2002 Jun 21.

7.

Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes.

de Mareuil J, Mabrouk K, Doria E, Moulard M, de Chasteigner S, Oughideni R, van Rietschoten J, Rochat H, De Waard M, Sabatier JM.

Antiviral Res. 2002 Jun;54(3):175-88.

PMID:
12062390
8.

Genetic control of infection of primary macrophages with T-cell-tropic strains of HIV-1.

Hirsch I, de Mareuil J, Salaun D, Chermann JC.

Virology. 1996 May 1;219(1):257-61.

9.

Fusogenic determinants of highly cytopathic subtype D Zairian isolate HIV-1 NDK.

De Mareuil J, Salaun D, Chermann JC, Hirsch I.

Virology. 1995 Jun 1;209(2):649-53.

10.

Restriction of HIV-1 replication in intestinal cells is genetically controlled by the gag-pol region of the HIV-1 genome.

De Mareuil J, Guettari N, Bolmont C, Salaun D, Baillon JG, Hostomsky Z, Hirsch I.

Virology. 1995 Feb 20;207(1):160-7.

11.

Neutralizing antibodies against highly cytopathic Zairian human immunodeficiency type-1 virus (HIV-1) NDK are present in sera outside Africa.

Machado AA, Bakpabua M, Salaun D, de Mareuil J, Krchnak V, MacGregor RR, Chermann JC, Hirsch I.

Vaccine. 1995 Feb;13(3):321-5.

PMID:
7631521
12.

Lectin-mediated effects on HIV type 1 infection in vitro.

Hammar L, Hirsch I, Machado AA, De Mareuil J, Baillon JG, Bolmont C, Chermann JC.

AIDS Res Hum Retroviruses. 1995 Jan;11(1):87-95.

PMID:
7734200
13.

Lectin effects on HIV-1 infectivity.

Hammar L, Hirsch I, Machado A, De Mareuil J, Baillon J, Chermann JC.

Ann N Y Acad Sci. 1994 Jun 6;724:166-9.

PMID:
8030938

Supplemental Content

Loading ...
Support Center